Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Hepatitis

Free Subscription Articles published in Hepatology Retrieve available abstracts of 205 articles: HTML format

Single Articles

June 2023
1. DA BL
   Clinical trials in hepatitis D virus: Measuring success.
   Hepatology. 2023;77:2147-2157.
   PubMed     Abstract available
   
   
   May 2023
2. HUANG DQ, Tran A, Yeh ML, Yasuda S, et al
   Antiviral therapy substantially reduces hepatocellular carcinoma risk in chronic Hepatitis B patients in the indeterminate phase.
   Hepatology. 2023 May 16. doi: 10.1097/HEP.0000000000000459.
   PubMed     Abstract available
   
   
   
3. TERRAULT N, Torres H, Price J, Bhattacharya D, et al
   The national hepatitis c elimination program - AASLD's coalition and call to action.
   Hepatology. 2023 May 12. doi: 10.1097/HEP.0000000000000444.
   PubMed    
   
   
   
4. GENSHAFT AS, Subudhi S, Keo A, Sanchez Vasquez JD, et al
   Single-cell RNA sequencing of liver fine-needle aspirates captures immune diversity in the blood and liver in chronic hepatitis B patients.
   Hepatology. 2023 May 10. doi: 10.1097/HEP.0000000000000438.
   PubMed     Abstract available
   
   
   
5. NG CH, Chan KE, Muthiah M, Tan C, et al
   Examining the interim proposal for name change to steatotic liver disease in the US population.
   Hepatology. 2023;77:1712-1721.
   PubMed     Abstract available
   
   
   
6. HOWELL J, Seaman C, Wallace J, Xiao Y, et al
   Pathway to global elimination of hepatitis B: HBV cure is just the first step.
   Hepatology. 2023 May 1. doi: 10.1097/HEP.0000000000000430.
   PubMed     Abstract available
   
   
   April 2023
7. SONNEVELD MJ, Brouwer WP, Janssen HLA
   Treatment of diabetes mellitus in patients with chronic hepatitis B: Are SGLT2 inhibitors hitting the sweet spot?
   Hepatology. 2023 Apr 27. doi: 10.1097/HEP.0000000000000424.
   PubMed    
   
   
   
8. GHANY MG, King WC, Hinerman AS, Lok AS, et al
   Use of HBV RNA and hepatitis B core-related antigen to predict change in serological status and disease activity in CHB.
   Hepatology. 2023 Apr 20. doi: 10.1097/HEP.0000000000000413.
   PubMed     Abstract available
   
   
   
9. DIETZ J, Lohmann V
   Therapeutic preparedness: DAA resistant Hepatitis C virus variants in vitro and in vivo.
   Hepatology. 2023 Apr 15. doi: 10.1097/HEP.0000000000000405.
   PubMed    
   
   
   
10. FERNANDEZ-ANTUNEZ C, Wang K, Fahnoe U, Mikkelsen LS, et al
    Characterization of multi-DAA resistance using a novel hepatitis C virus genotype 3a infectious culture system.
    Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000353.
    PubMed     Abstract available
    
    
    
11. VO-QUANG E, Soulier A, Ndebi M, Rodriguez C, et al
    Virological characterization of treatment failures and retreatment outcomes in patients infected with "unusual" HCV genotype 1 subtypes.
    Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000379.
    PubMed     Abstract available
    
    
    
12. CHAO X, Wang S, Ma X, Zhang C, et al
    Persistent mTORC1 activation due to loss of liver tuberous sclerosis complex 1 promotes liver injury in alcoholic hepatitis.
    Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000373.
    PubMed     Abstract available
    
    
    
13. STEINMANN S, Lohse AW
    Treatment of autoimmune hepatitis: Budesonide does not solve our problems.
    Hepatology. 2023;77:1071-1073.
    PubMed    
    
    
    
14. TAN DJH, Setiawan VW, Ng CH, Lim WH, et al
    Global burden of liver cancer in males and females: Changing etiological basis and the growing contribution of NASH.
    Hepatology. 2023;77:1150-1163.
    PubMed     Abstract available
    
    
    March 2023
15. MAK LY, Yuen MF, Seto WK
    Reply: hepatic steatosis and glycemic burden in chronic hepatitis b.
    Hepatology. 2023 Mar 20. doi: 10.1097/HEP.0000000000000374.
    PubMed    
    
    
    
16. HUANG SC, Kao JH
    Letter to the Editor: Hepatic steatosis and glycemic burden in chronic hepatitis B.
    Hepatology. 2023 Mar 20. doi: 10.1097/HEP.0000000000000371.
    PubMed    
    
    
    
17. DE CARVALHO RIBEIRO M, Iracheta-Vellve A, Babuta M, Calenda CD, et al
    Alcohol-induced extracellular asc specks perpetuate liver inflammation and damage in alcoholic hepatitis even after alcohol cessation.
    Hepatology. 2023 Mar 3. doi: 10.1097/HEP.0000000000000298.
    PubMed     Abstract available
    
    
    
18. WU X, Fan X, McMullen MR, Miyata T, et al
    Macrophage-derived MLKL in alcohol-associated liver disease: Regulation of phagocytosis.
    Hepatology. 2023;77:902-919.
    PubMed     Abstract available
    
    
    
19. LEGGIO L, Mellinger JL
    Alcohol use disorder in community management of chronic liver diseases.
    Hepatology. 2023;77:1006-1021.
    PubMed     Abstract available
    
    
    February 2023
20. SZABO G, Mitchell M, Dasarathy S, McClain C, et al
    Reply: Survival in placebo-treated patients with severe alcoholic hepatitis".
    Hepatology. 2023 Feb 24. doi: 10.1097/HEP.0000000000000337.
    PubMed    
    
    
    
21. VAN MELKEBEKE L, Pollentier L, Van der Merwe S, Nevens F, et al
    Letter to the editor: survival in placebo-treated patients with severe alcoholic hepatitis.
    Hepatology. 2023 Feb 24. doi: 10.1097/HEP.0000000000000336.
    PubMed    
    
    
    
22. 
    Sociodemographic and geographic differences in the US epidemiology of autoimmune hepatitis with and without cirrhosis: Erratum.
    Hepatology. 2023 Feb 21. doi: 10.1097/HEP.0000000000000348.
    PubMed    
    
    
    
23. ETZION O, Hamid S, Lurie Y, Gane EJ, et al
    Treatment of chronic hepatitis d with peginterferon lambda - the phase 2 LIMT-1 clinical trial.
    Hepatology. 2023 Feb 20. doi: 10.1097/HEP.0000000000000309.
    PubMed     Abstract available
    
    
    
24. SCHRADER JA, Burkard TL, Bruggemann Y, Gomer A, et al
    Epidermal growth factor receptor modulates hepatitis e virus entry in human hepatocytes -HEP-22-1113.
    Hepatology. 2023 Feb 7. doi: 10.1097/HEP.0000000000000308.
    PubMed     Abstract available
    
    
    
25. ABDUL MAJEED N, Zehnder B, Koh C, Heller T, et al
    Hepatitis delta: epidemiology to recent advances in therapeutic agents.
    Hepatology. 2023 Feb 6. doi: 10.1097/HEP.0000000000000331.
    PubMed    
    
    
    
26. LUO W, Zhang Y, Zhang T
    Letter to the editor: Successful treatment of multidrug-resistant hepatis C after >12 months of continuous therapy with direct-acting antivirals.
    Hepatology. 2023;77:E26-E27.
    PubMed    
    
    
    
27. LISKER-MELMAN M, Wahed AS, Ghany MG, Chung RT, et al
    HBV transcription and translation persist despite viral suppression in HBV-HIV co-infected patients on antiretroviral therapy.
    Hepatology. 2023;77:594-605.
    PubMed     Abstract available
    
    
    January 2023
28. HSU CC, Dodge JL, Weinberg E, Im G, et al
    Multi-Centered study of patient outcomes after declined for early liver transplantation in severe Alcohol-associated hepatitis.
    Hepatology. 2023 Jan 19. doi: 10.1097/HEP.0000000000000267.
    PubMed     Abstract available
    
    
    
29. DIAZ-GONZALEZ A, Hernandez-Guerra M, Perez-Medrano I, Sapena V, et al
    Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predni(so)lone administration.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000018.
    PubMed     Abstract available
    
    
    
30. WU J, Kim A, Wu X, Ray S, et al
    5S rRNA pseudogene transcripts are associated with interferon production and inflammatory responses in alcohol-associated hepatitis.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000024.
    PubMed     Abstract available
    
    
    October 2022
31. BALOG S, Fujiwara R, Pan SQ, El-Baradie KB, et al
    Emergence of highly profibrotic and proinflammatory Lrat(+) Fbln2(+) hepatic stellate cell subpopulation in alcoholic hepatitis.
    Hepatology. 2022 Oct 1. doi: 10.1002/hep.32793.
    PubMed     Abstract available
    
    
    September 2022
32. YIP TC, Wong VW, Wong GL
    Does hepatic steatosis impact chronic hepatitis B?
    Hepatology. 2022 Sep 24. doi: 10.1002/hep.32803.
    PubMed    
    
    
    
33. MAK LY, Hui RW, Lee CH, Mao X, et al
    Glycemic burden and the risk of adverse hepatic outcomes in patients with chronic hepatitis B with type 2 diabetes.
    Hepatology. 2022 Sep 21. doi: 10.1002/hep.32716.
    PubMed     Abstract available
    
    
    
34. JACHS M, Tillmann HL
    Editorial: It's not all about the virus - on the importance of modifiable lifestyle factors in the development of hepatocellular carcinoma in chronic hepatitis B.
    Hepatology. 2022 Sep 17. doi: 10.1002/hep.32798.
    PubMed    
    
    
    
35. YING D, He Q, Tian W, Chen Y, et al
    Urine Is a Viral Antigen Reservoir in Hepatitis E Virus Infection.
    Hepatology. 2022 Sep 15. doi: 10.1002/hep.32745.
    PubMed     Abstract available
    
    
    
36. MAO X, Cheung KS, Peng C, Mak LY, et al
    Steatosis, HBV-related hepatocellular carcinoma, cirrhosis & HBsAg seroclearance: a systematic review and meta-analysis.
    Hepatology. 2022 Sep 15. doi: 10.1002/hep.32792.
    PubMed     Abstract available
    
    
    
37. ALZUA GP, Pihl AF, Offersgaard A, Velazquez-Moctezuma R, et al
    Identification of novel neutralizing determinants for protection against hepatitis C virus.
    Hepatology. 2022 Sep 3. doi: 10.1002/hep.32772.
    PubMed     Abstract available
    
    
    
38. PAL S, Dey D, Chakraborty BC, Nandi M, et al
    Diverse facets of MDSC in different phases of chronic HBV infection: Impact on HBV-specific T-cell response and homing.
    Hepatology. 2022;76:759-774.
    PubMed     Abstract available
    
    
    August 2022
39. LEE HM, Lidofsky SD, Taddei TH, Townshend-Bulson LJ, et al
    Attacking the Public Health Crisis of Hepatocellular Carcinoma at its Roots.
    Hepatology. 2022 Aug 21. doi: 10.1002/hep.32741.
    PubMed    
    
    
    
40. SERPER M, Kaplan DE, Taddei TH, Tapper EB, et al
    Non-selective Beta Blockers, Hepatic Decompensation and Mortality in Cirrhosis: A National Cohort Study.
    Hepatology. 2022 Aug 19. doi: 10.1002/hep.32737.
    PubMed     Abstract available
    
    
    
41. LOUREIRO D, Tout I, Narguet S, Bed CM, et al
    Mitochondrial stress in advanced fibrosis and cirrhosis associated with chronic hepatitis B, chronic hepatitis C or nonalcoholic steatohepatitis.
    Hepatology. 2022 Aug 16. doi: 10.1002/hep.32731.
    PubMed     Abstract available
    
    
    
42. WU Y, Hao X, Wei H, Sun R, et al
    TIGIT blockade elicits potent anti-tumor immunity in naturally occurring hepatitis B virus-related hepatocellular carcinoma in mice.
    Hepatology. 2022 Aug 8. doi: 10.1002/hep.32715.
    PubMed     Abstract available
    
    
    July 2022
43. TRUDEAU S, Mendiratta V, Dababneh Y, Hollingsworth J, et al
    Letter to the Editor: Successful treatment of multidrug resistant hepatitis C after >12 months of continuous therapy with direct-acting antivirals.
    Hepatology. 2022 Jul 27. doi: 10.1002/hep.32688.
    PubMed    
    
    
    
44. SHEHRYAR M, Asif MZ, Umair M
    Letter to the Editor: County-Level Variation in Hepatitis C Virus Mortality and Trends in the United States, 2005-2017.
    Hepatology. 2022 Jul 26. doi: 10.1002/hep.32685.
    PubMed    
    
    
    
45. NASSAL M
    How many steps to a feasible mouse model of hepatitis B virus infection?
    Hepatology. 2022 Jul 24. doi: 10.1002/hep.32684.
    PubMed    
    
    
    
46. ELSHEIKH R, Tien HT, Makram AM, Van NT, et al
    Acute Hepatitis of Unknown Origin in Children: Behind the Statistics.
    Hepatology. 2022 Jul 21. doi: 10.1002/hep.32682.
    PubMed     Abstract available
    
    
    
47. PAPATHEODORIDI M, Lok AS, Papatheodoridis GV
    Letter to the Editor: Hepatitis B virus reactivation in immune checkpoint inhibitor-based combination therapies for hepatocellular carcinoma - Authors' reply.
    Hepatology. 2022 Jul 20. doi: 10.1002/hep.32673.
    PubMed    
    
    
    
48. JIN ZC, Chen JJ, Luo B, Zhang WH, et al
    Letter to the Editor: Hepatitis B virus reactivation in immune checkpoint inhibitor-based combination therapies for hepatocellular carcinoma.
    Hepatology. 2022 Jul 15. doi: 10.1002/hep.32672.
    PubMed    
    
    
    
49. BITTERMANN T, Lewis JD, Levy C, Goldberg DS, et al
    Sociodemographic and geographic differences in the U.S. epidemiology of autoimmune hepatitis with and without cirrhosis.
    Hepatology. 2022 Jul 10. doi: 10.1002/hep.32653.
    PubMed     Abstract available
    
    
    
50. FUNG S, Choi HSJ, Gehring A, Janssen HLA, et al
    Getting to HBV cure: The promising paths forward.
    Hepatology. 2022;76:233-250.
    PubMed     Abstract available
    
    
    
51. WU CR, Kim HJ, Sun CP, Chung CY, et al
    Mapping the conformational epitope of a therapeutic monoclonal antibody against HBsAg by in vivo selection of HBV escape variants.
    Hepatology. 2022;76:207-219.
    PubMed     Abstract available
    
    
    
52. SINGH SP, Mishra AK, Jindal A
    IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcoholic hepatitis - more questions than answers !
    Hepatology. 2022 Jul 1. doi: 10.1002/hep.32648.
    PubMed    
    
    
    
53. GUPTA S, Nath P, Anand AC
    Letter to the Editor: Combination treatment with IL- 1 antagonist, pentoxifylline & zinc for severe alcoholic hepatitis: Are we there yet?
    Hepatology. 2022 Jul 1. doi: 10.1002/hep.32646.
    PubMed    
    
    
    June 2022
54. BARNES E, Cooke GS, Lauer G, Chung RT, et al
    Implementation of a Controlled Human Infection Model for Evaluation of HCV Vaccine Candidates.
    Hepatology. 2022 Jun 23. doi: 10.1002/hep.32632.
    PubMed     Abstract available
    
    
    
55. ZHAO K, Guo F, Wang J, Zhong Y, et al
    Limited disassembly of cytoplasmic hepatitis B virus nucleocapsids restricts viral infection in murine hepatic cells.
    Hepatology. 2022 Jun 19. doi: 10.1002/hep.32622.
    PubMed     Abstract available
    
    
    
56. XU C, Fan J, Liu D, Tuerdi A, et al
    Alpha-kinase 1 (ALPK1) Agonist, DF-006 Demonstrates Potent Efficacy in Murine and Primary Human Hepatocyte Models of Hepatitis B.
    Hepatology. 2022 Jun 14. doi: 10.1002/hep.32614.
    PubMed     Abstract available
    
    
    
57. MA X, Chen A, Melo L, Clemente-Sanchez A, et al
    Loss of hepatic DRP1 exacerbates alcoholic hepatitis by inducing megamitochondria and mitochondrial maladaptation.
    Hepatology. 2022 Jun 13. doi: 10.1002/hep.32604.
    PubMed     Abstract available
    
    
    
58. AHMAD A
    Letter to the Editor: Recovery and outcomes of patients denied early liver transplantation for severe alcohol-associated hepatitis.
    Hepatology. 2022 Jun 11. doi: 10.1002/hep.32607.
    PubMed     Abstract available
    
    
    
59. AHMAD A, Chaudhry HUR
    Letter to the Editor: Outcomes of pregnancy in autoimmune hepatitis: A population-based study.
    Hepatology. 2022 Jun 10. doi: 10.1002/hep.32600.
    PubMed    
    
    
    
60. WANG CY, Deng Y, Li P, Zheng S, et al
    Prediction of biochemical nonresolution in patients with chronic drug-induced liver injury: A large multicenter study.
    Hepatology. 2022;75:1373-1385.
    PubMed     Abstract available
    
    
    May 2022
61. HARRINGTON C, Krishnan S, Mack CL, Cravedi P, et al
    Non-Invasive Biomarkers for the Diagnosis and Management of Autoimmune Hepatitis.
    Hepatology. 2022 May 25. doi: 10.1002/hep.32591.
    PubMed     Abstract available
    
    
    
62. CHUNG Y, Heneghan MA
    Reply to: Medical therapy of autoimmune hepatitis in pregnancy.
    Hepatology. 2022 May 19. doi: 10.1002/hep.32579.
    PubMed    
    
    
    
63. EFE C, Purnak T
    Medical therapy of Autoimmune hepatitis in pregnancy.
    Hepatology. 2022 May 18. doi: 10.1002/hep.32576.
    PubMed    
    
    
    
64. EFE C, Kulkarni AV, Beretta-Piccoli BT, Magro B, et al
    Liver injury after SARS-CoV-2 vaccination: Features of immune-mediated hepatitis, role of corticosteroid therapy and outcome.
    Hepatology. 2022 May 14. doi: 10.1002/hep.32572.
    PubMed     Abstract available
    
    
    
65. NEUMANN-HAEFELIN C, Thimme R
    Another important step towards a prophylactic vaccine against hepatitis C.
    Hepatology. 2022 May 3. doi: 10.1002/hep.32557.
    PubMed    
    
    
    
66. MULCAHY VL, Mells GF
    Commentary on Genome-wide Meta-analysis Identifies Novel Susceptibility Loci for Autoimmune Hepatitis Type 1.
    Hepatology. 2022 May 2. doi: 10.1002/hep.32547.
    PubMed    
    
    
    
67. PAPATHEODORIDI M, Tampaki M, Lok AS, Papatheodoridis GV, et al
    Risk of HBV reactivation during therapies for HCC: A systematic review.
    Hepatology. 2022;75:1257-1274.
    PubMed     Abstract available
    
    
    April 2022
68. KUMAR A, Rajani D, Kumar S
    Letter to the editor: HBV genotype: a significant risk factor in determining which patients with chronic HBV infection should undergo surveillance for HCC: The hepatitis B Alaska study.
    Hepatology. 2022 Apr 28. doi: 10.1002/hep.32544.
    PubMed    
    
    
    
69. WOLFISBERG R, Thorselius CE, Salinas E, Elrod E, et al
    Neutralization and receptor usage of infectious culture derived rat hepacivirus as a model for hepatitis C.
    Hepatology. 2022 Apr 21. doi: 10.1002/hep.32535.
    PubMed     Abstract available
    
    
    
70. LUCEY MR, Thursz M
    We need a new approach to clinical trials in alcohol-associated hepatitis. Is there a lesson in RECOVERY?
    Hepatology. 2022 Apr 13. doi: 10.1002/hep.32523.
    PubMed    
    
    
    
71. COFFIN CS
    The remarkable success of the vaccine for a killer virus: Hepatitis B.
    Hepatology. 2022 Apr 11. doi: 10.1002/hep.32346.
    PubMed    
    
    
    
72. DEFFIEU MS, Clement CMH, Dorobantu CM, Partiot E, et al
    Occludin stalls HCV particle dynamics apart from hepatocyte tight junctions, promoting virion internalization.
    Hepatology. 2022 Apr 7. doi: 10.1002/hep.32514.
    PubMed     Abstract available
    
    
    
73. WAT C, Gane E, Yuen MF, Pavlovic V, et al
    Reply.
    Hepatology. 2022;75:1050-1051.
    PubMed    
    
    
    March 2022
74. SUNDARAM V, Jalan R
    Letter to the editor: the role of acute-on-chronic liver failure in predicting recovery in severe alcoholic hepatitis.
    Hepatology. 2022 Mar 31. doi: 10.1002/hep.32495.
    PubMed    
    
    
    
75. DENG R, Liu S, Shen S, Guo H, et al
    Circulating hepatitis B virus RNA: From biology to clinical applications.
    Hepatology. 2022 Mar 28. doi: 10.1002/hep.32479.
    PubMed     Abstract available
    
    
    
76. SZABO G, Mitchell M, McClain CJ, Dasarathy S, et al
    IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol-associated hepatitis.
    Hepatology. 2022 Mar 27. doi: 10.1002/hep.32478.
    PubMed     Abstract available
    
    
    
77. BRUCE MG, Bruden D, Hurlburt D, Morris J, et al
    Protection and Antibody Levels 35 Years after Primary Series with Hepatitis B Vaccine and Response to a Booster Dose.
    Hepatology. 2022 Mar 23. doi: 10.1002/hep.32474.
    PubMed     Abstract available
    
    
    
78. LOUKACHOV V, van Dort K, Erken R, Reesink HW, et al
    Reponse to: Letter to the Editor concerning Quantified integrated hepatitis B virus is related to viral activity in chronic hepatitis B patients.
    Hepatology. 2022 Mar 23. doi: 10.1002/hep.32472.
    PubMed    
    
    
    
79. DONNISON T, McGregor J, Chinnakannan S, Hutchings C, et al
    A pan-genotype hepatitis C virus viral vector vaccine generates T-cells and neutralizing antibodies in mice.
    Hepatology. 2022 Mar 21. doi: 10.1002/hep.32470.
    PubMed     Abstract available
    
    
    
80. HE Q, Zhang F, Shu J, Li S, et al
    Immunocompromised rabbit model of chronic hepatitis E reveals liver fibrosis and distinct efficacy of different vaccination strategies.
    Hepatology. 2022 Mar 12. doi: 10.1002/hep.32455.
    PubMed     Abstract available
    
    
    
81. HOWELL J, Hellard M
    Making child's play of tolerance: Defining the immune-viral interplay during combination entecavir and pegylated interferon therapy for immune tolerant hepatitis B infection.
    Hepatology. 2022 Mar 9. doi: 10.1002/hep.32450.
    PubMed    
    
    
    
82. GAVRISHEVA S, Abdurakhmanov D, Milovanova S, Nikulkina E, et al
    Letter to the Editor: High rate of clinical and immunological response in patients with HCV-associated cryoglobulinemia.
    Hepatology. 2022 Mar 8. doi: 10.1002/hep.32425.
    PubMed    
    
    
    
83. KANWAL F, Khaderi S, Singal AG, Marrero JA, et al
    Risk Factors for Hepatocellular Cancer in Contemporary Cohorts of Patients with Cirrhosis.
    Hepatology. 2022 Mar 1. doi: 10.1002/hep.32434.
    PubMed     Abstract available
    
    
    February 2022
84. PATWA AK, Rungta S, Kumar V
    Nanoparticle therapeutic vaccine for hepatitis B: an unfulfilled dream.
    Hepatology. 2022 Feb 28. doi: 10.1002/hep.32421.
    PubMed    
    
    
    
85. D'AMBROSIO R, Lampertico P
    Is it time to refine HCC surveillance strategies in HCV cured patients?
    Hepatology. 2022 Feb 26. doi: 10.1002/hep.32430.
    PubMed    
    
    
    
86. ZHANG J, Zhao T, Wei L, Wu Y, et al
    Reply: epsilonPA-44 may expand the arsenal for chronic hepatitis B combination treatment towards functional cure.
    Hepatology. 2022 Feb 24. doi: 10.1002/hep.32423.
    PubMed    
    
    
    
87. PERRILLO RP, Lin HS, Schwarz KB, Rosenthal P, et al
    Changes in serum hepatitis B surface and e antigen, IP-10, and aminotransferase levels during combination therapy of immune tolerant chronic hepatitis B.
    Hepatology. 2022 Feb 21. doi: 10.1002/hep.32400.
    PubMed     Abstract available
    
    
    
88. LI Y, Sun Y, Liu Y, Wang B, et al
    Genome-wide Meta-analysis Identifies Novel Susceptibility Loci for Autoimmune Hepatitis Type 1.
    Hepatology. 2022 Feb 19. doi: 10.1002/hep.32417.
    PubMed     Abstract available
    
    
    
89. CHUNG YY, Heneghan MA
    Autoimmune hepatitis in pregnancy: pearls and pitfalls.
    Hepatology. 2022 Feb 19. doi: 10.1002/hep.32410.
    PubMed     Abstract available
    
    
    
90. INDOLFI G, Kelly D, Nebbia G, Iorio R, et al
    Sofosbuvir-Velpatasvir-Voxilaprevir in Adolescents 12 to 17 Years Old With Hepatitis C Virus Infection.
    Hepatology. 2022 Feb 3. doi: 10.1002/hep.32393.
    PubMed     Abstract available
    
    
    
91. TU T, Zhang H
    Viral integrations in chronic Hepatitis B infection: purposeless passenger or problematic promoter of persistence?
    Hepatology. 2022 Feb 2. doi: 10.1002/hep.32388.
    PubMed    
    
    
    
92. YANG Y, Choi J, Chen Y, Invernizzi P, et al
    E. coli and the etiology of human PBC: Antimitochondrial antibodies and spreading determinants.
    Hepatology. 2022;75:266-279.
    PubMed     Abstract available
    
    
    
93. WANG X, Wei Z, Cheng B, Li J, et al
    Endoplasmic reticulum stress promotes HBV production by enhancing use of the autophagosome/multivesicular body axis.
    Hepatology. 2022;75:438-454.
    PubMed     Abstract available
    
    
    January 2022
94. HUANG V, Lewin C, Novy P
    Leveraging universal adult vaccination as part of a multipronged approach to eliminate hepatitis B in the US.
    Hepatology. 2022 Jan 31. doi: 10.1002/hep.32376.
    PubMed    
    
    
    
95. JANG H, Lee YB, Moon H, Chung JW, et al
    Aspirin Use and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B With or Without Cirrhosis.
    Hepatology. 2022 Jan 31. doi: 10.1002/hep.32380.
    PubMed     Abstract available
    
    
    
96. PAN CQ, Jacobson IM, Martin P, Kwo P, et al
    Letter to the editor: Both universal screening and vaccination are essential components of a multipronged approach to hepatitis B elimination.
    Hepatology. 2022 Jan 28. doi: 10.1002/hep.32366.
    PubMed    
    
    
    
97. ERKEN R, Loukachov V, van Dort K, van den Hurk A, et al
    Quantified integrated hepatitis B virus is related to viral activity in chronic hepatitis B patients.
    Hepatology. 2022 Jan 24. doi: 10.1002/hep.32352.
    PubMed     Abstract available
    
    
    
98. HUANG CH, Fan JH, Jeng WJ, Chang ST, et al
    Innate-like bystander-activated CD38(+) HLA-DR(+) CD8(+) T cells play a pathogenic role in patients with chronic hepatitis C.
    Hepatology. 2022 Jan 21. doi: 10.1002/hep.32349.
    PubMed     Abstract available
    
    
    
99. PARK H, Lo-Ciganic WH, Huang J, Wu Y, et al
    Machine Learning Algorithms for Predicting Direct-Acting Antiviral Treatment Failure in Chronic Hepatitis C: An HCV-TARGET Analysis.
    Hepatology. 2022 Jan 16. doi: 10.1002/hep.32347.
    PubMed     Abstract available
    
    
    
100. LOCKART I, Yeo MGH, Hajarizadeh B, Dore GJ, et al
     Hepatocellular carcinoma incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis.
     Hepatology. 2022 Jan 14. doi: 10.1002/hep.32341.
     PubMed     Abstract available
     
     
     
101. PAN JJ, Razumilava N
     Corticosteroids for high-grade immune checkpoint inhibitor-mediated hepatitis: is less more?
     Hepatology. 2022 Jan 10. doi: 10.1002/hep.32330.
     PubMed    
     
     
     
102. SANDMANN L, Cornberg M
     Hepatocellular carcinoma and hepatitis B virus reactivation - a preventable condition not to be missed.
     Hepatology. 2022 Jan 10. doi: 10.1002/hep.32333.
     PubMed    
     
     
     
103. JINDAL A
     Oral antivirals in treatment naive chronic hepatitis C infection.
     Hepatology. 2022 Jan 5. doi: 10.1002/hep.32311.
     PubMed    
     
     
     
104. GINES P, Castera L, Lammert F, Graupera I, et al
     Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases.
     Hepatology. 2022;75:219-228.
     PubMed     Abstract available
     
     
     December 2021
105. COHEN C, Moraras K, Jackson M, Kamischke M, et al
     Letter to the Editor: Importance of Universal Screening for Chronic Hepatitis B Infection in Adults in the United States.
     Hepatology. 2021 Dec 24. doi: 10.1002/hep.32304.
     PubMed    
     
     
     
106. CHEN VL, Ramrakhiani NS, Nguyen MH
     Hepatitis B screening-Universal or simplified semi-targeted but not the status quo.
     Hepatology. 2021 Dec 24. doi: 10.1002/hep.32303.
     PubMed    
     
     
     
107. KONDILI LA, Monti M, Quaranta MG, Gragnani L, et al
     A prospective study of DAA Effectiveness and Relapse Risk in HCV Cryoglobulinemic Vasculitis by the Italian PITER Cohort.
     Hepatology. 2021 Dec 16. doi: 10.1002/hep.32281.
     PubMed     Abstract available
     
     
     
108. SUZUKI Y, Kakisaka K, Takikawa Y
     Letter to the Editor: Autoimmune hepatitis after COVID-19 vaccination: Need for population based-epidemiological study.
     Hepatology. 2021 Dec 13. doi: 10.1002/hep.32280.
     PubMed    
     
     
     
109. MUSTO J, Lucey MR, Rice J
     Spontaneous recovery in patients denied early liver transplantation for severe alcoholic hepatitis-Need a closer look!
     Hepatology. 2021 Dec 10. doi: 10.1002/hep.32275.
     PubMed    
     
     
     
110. JINDAL A
     Letter to the editor: Spontaneous recovery in patients denied early liver transplantation for severe alcoholic hepatitis-Need a closer look!
     Hepatology. 2021 Dec 10. doi: 10.1002/hep.32276.
     PubMed    
     
     
     
111. WEI L, Ploss A
     Rise above the stress-Endoplasmic reticulum stress and autophagy enhance the release of hepatitis B virus subparticles.
     Hepatology. 2021 Dec 10. doi: 10.1002/hep.32273.
     PubMed    
     
     
     
112. LIBRERO JIMENEZ M, Lopez Garrido MA, Fernandez Cano MC
     Letter to the editor: Reactivation of HBV triggered by SARS-CoV-2 in a patient with cirrhosis.
     Hepatology. 2021 Dec 8. doi: 10.1002/hep.32271.
     PubMed    
     
     
     
113. CAO Z, Gui H, Sheng Z, Xin H, et al
     Letter to the editor: Exacerbation of autoimmune hepatitis after COVID-19 vaccination.
     Hepatology. 2021 Dec 4. doi: 10.1002/hep.32269.
     PubMed     Abstract available
     
     
     
114. YURDAYDIN C, Keskin O, Yurdcu E, Caliskan A, et al
     A Phase ii dose finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis.
     Hepatology. 2021 Dec 3. doi: 10.1002/hep.32259.
     PubMed     Abstract available
     
     
     
115. MURAYAMA A, Ozaki A, Saito H, Sawano T, et al
     Are Clinical Practice Guideline for Hepatitis C by the American Association for the Study of Liver Disease and Infectious Diseases Society of America Evidence-based? Financial Conflicts of Interest and Assessment of Quality of Evidence and Strength of
     Hepatology. 2021 Dec 2. doi: 10.1002/hep.32262.
     PubMed     Abstract available
     
     
     
116. HE WQ, Guo GN, Li C
     The impact of hepatitis B vaccination in United States, 1999-2018.
     Hepatology. 2021 Dec 2. doi: 10.1002/hep.32265.
     PubMed     Abstract available
     
     
     
117. WYATT B, Perumalswami PV, Mageras A, Miller M, et al
     A Digital Case-Finding Algorithm for Diagnosed but Untreated Hepatitis C: A Tool for Increasing Linkage to Treatment and Cure.
     Hepatology. 2021;74:2974-2987.
     PubMed     Abstract available
     
     
     
118. ISNARD P, Larue M, Pitsch A, Duong Van Huyen JP, et al
     A Simple Bacterium Links Heart Infection to Inflammatory Liver Disease.
     Hepatology. 2021;74:3549-3551.
     PubMed    
     
     
     November 2021
119. PALLA P, Vergadis C, Sakellariou S, Androutsakos T, et al
     'Letter to the editor: Response to letter concerning our patient with post-vaccination autoimmune hepatitis like syndrome'.
     Hepatology. 2021 Nov 19. doi: 10.1002/hep.32248.
     PubMed     Abstract available
     
     
     
120. MUNGMUNPUNTIPANTIP R, Wiwanitkit V
     Lettter to the editor on "Autoimmune hepatitis after COVID-19 vaccination".
     Hepatology. 2021 Nov 19. doi: 10.1002/hep.32249.
     PubMed     Abstract available
     
     
     
121. WANG Y, Li Y, Zai W, Hu K, et al
     Hepatitis B Virus cccDNA Minichromosomes in Distinct Epigenetic Transcriptional States Differ in Their Vulnerability to Damage.
     Hepatology. 2021 Nov 15. doi: 10.1002/hep.32245.
     PubMed     Abstract available
     
     
     
122. POLITI J, Guerras JM, Donat M, Belza MJ, et al
     Favorable impact in Hepatitis C related mortality following free-access to direct-acting antivirals in Spain.
     Hepatology. 2021 Nov 12. doi: 10.1002/hep.32237.
     PubMed     Abstract available
     
     
     
123. TABERNERO D, Cortese MF, Rando-Segura A, Buti M, et al
     Letter to the Editor: standardization of HBV RNA assay for the different phases of chronic hepatitis B is essential.
     Hepatology. 2021 Nov 10. doi: 10.1002/hep.32227.
     PubMed     Abstract available
     
     
     
124. TERRAULT NA, Wahed AS, Feld JJ, Cooper SL, et al
     Incidence and Prediction of HBsAg Seroconversion in a Prospective Multi-ethnic HBeAg-Negative Chronic Hepatitis B Cohort.
     Hepatology. 2021 Nov 7. doi: 10.1002/hep.32231.
     PubMed     Abstract available
     
     
     
125. KUIPERY A, Sanchez Vasquez JD, Mehrotra A, Feld JJ, et al
     Immunomodulation and RNA interference alter Hepatitis B Virus-specific CD8 T cell recognition of infected HepG2-NTCP.
     Hepatology. 2021 Nov 7. doi: 10.1002/hep.32230.
     PubMed     Abstract available
     
     
     
126. ROY A, Dhiman RK
     Letter to the Editor: Recurrent Cryoglobulinemic Vasculitis in the Era of Direct-Acting Antivirals: A Story Beyond Sustained Virological Response 12.
     Hepatology. 2021;74:2909.
     PubMed    
     
     
     
127. GHANY MG, King WC, Lisker-Melman M, Lok ASF, et al
     Comparison of HBV RNA and Hepatitis B Core Related Antigen With Conventional HBV Markers Among Untreated Adults With Chronic Hepatitis B in North America.
     Hepatology. 2021;74:2395-2409.
     PubMed     Abstract available
     
     
     
128. SHEN Y, Cingolani F, Malik SA, Wen J, et al
     Sex-Specific Regulation of Interferon-gamma Cytotoxicity in Mouse Liver by Autophagy.
     Hepatology. 2021;74:2745-2758.
     PubMed     Abstract available
     
     
     
129. LEE BT, Tana MM, Kahn JA, Dara L, et al
     We Are Not Immune: Racial and Ethnic Disparities in Autoimmune Liver Diseases.
     Hepatology. 2021;74:2876-2887.
     PubMed     Abstract available
     
     
     
130. OTERO SANCHEZ L, Karakike E, Njimi H, Putignano A, et al
     Clinical Course and Risk Factors for Infection in Severe Forms of Alcohol-Associated Liver Disease.
     Hepatology. 2021;74:2714-2724.
     PubMed     Abstract available
     
     
     October 2021
131. BEKKI Y, Fenig Y
     Outcomes of Severe Alcohol-Related Hepatitis with or without Early Liver Transplantation.
     Hepatology. 2021 Oct 30. doi: 10.1002/hep.32219.
     PubMed     Abstract available
     
     
     
132. LI M, Wong D, Vogel AS, Sack JS, et al
     Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis.
     Hepatology. 2021 Oct 28. doi: 10.1002/hep.32215.
     PubMed     Abstract available
     
     
     
133. KHANAM A, Kottilil S, Tang LSY
     PD-1 Expressing CD8+CXCR5+ Follicular T Cells Constitute Effector Rather Than Exhaustive Phenotype in Patients with Chronic Hepatitis B.
     Hepatology. 2021 Oct 24. doi: 10.1002/hep.32210.
     PubMed     Abstract available
     
     
     
134. LAI CW, Nishio A, Hasan S, Kefalakes H, et al
     Spontaneous Clearance of Drug-Resistant Chronic Hepatitis C Virus Infection.
     Hepatology. 2021 Oct 18. doi: 10.1002/hep.32205.
     PubMed     Abstract available
     
     
     
135. HU K, Camila Perez-Matos M, Argemi J, Vilar E, et al
     Lipoprotein Z, A novel hepatotoxic lipoprotein, predicts outcome in alcoholic hepatitis.
     Hepatology. 2021 Oct 18. doi: 10.1002/hep.32203.
     PubMed     Abstract available
     
     
     
136. LAWITZ EJ, Shevell DE, Tirucherai GS, Du S, et al
     BMS-986263 in Patients with Advanced Hepatic Fibrosis: 36-Week Results from a Randomized, Placebo-Controlled Phase 2 Trial.
     Hepatology. 2021 Oct 4. doi: 10.1002/hep.32181.
     PubMed     Abstract available
     
     
     
137. KUSHNER T, Chappell CA
     Letter to the Editor: Pregnant Women and their Providers Want Direct-Acting Antivirals, and We Are Missing the Mark.
     Hepatology. 2021;74:2311-2312.
     PubMed    
     
     
     
138. MA Y, Su H, Yuksel M, Longhi MS, et al
     Human Leukocyte Antigen Profile Predicts Severity of Autoimmune Liver Disease in Children of European Ancestry.
     Hepatology. 2021;74:2032-2046.
     PubMed     Abstract available
     
     
     September 2021
139. YASSEEN AS, Kwong JC, Feld JJ, Kustra R, et al
     The viral hepatitis B care cascade: A population-based comparison of immigrant groups.
     Hepatology. 2021 Sep 19. doi: 10.1002/hep.32162.
     PubMed     Abstract available
     
     
     
140. PALLA P, Vergadis C, Sakellariou S, Androutsakos T, et al
     Letter to the editor: Autoimmune hepatitis after COVID-19 vaccination. A rare adverse effect?
     Hepatology. 2021 Sep 15. doi: 10.1002/hep.32156.
     PubMed     Abstract available
     
     
     
141. HUANG R, Liu J, Wang J, Li J, et al
     Letter to the Editor: Is hepatitis B virus genotype strongly associated with hepatocellular carcinoma risk in patients with chronic hepatitis B?
     Hepatology. 2021 Sep 14. doi: 10.1002/hep.32155.
     PubMed     Abstract available
     
     
     
142. RAMRAKHIANI NS, Chen VL, Le M, Yeo YH, et al
     Optimizing Hepatitis B Virus Screening in the United States Using a Simple Demographics-Based Model.
     Hepatology. 2021 Sep 8. doi: 10.1002/hep.32142.
     PubMed     Abstract available
     
     
     
143. COLL M, Arino S, Martinez-Sanchez C, Garcia-Pras E, et al
     Ductular Reaction Promotes Intrahepatic Angiogenesis Via Slit2-Robo1 Signaling.
     Hepatology. 2021 Sep 7. doi: 10.1002/hep.32140.
     PubMed     Abstract available
     
     
     
144. TAUBERT R, Engel B, Diestelhorst J, Hupa-Breier KL, et al
     Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis.
     Hepatology. 2021 Sep 2. doi: 10.1002/hep.32134.
     PubMed     Abstract available
     
     
     
145. DING WB, Wang MC, Yu J, Huang G, et al
     HBV/Pregenomic RNA Increases the Stemness and Promotes the Development of HBV-Related HCC Through Reciprocal Regulation With Insulin-Like Growth Factor 2 mRNA-Binding Protein 3.
     Hepatology. 2021;74:1480-1495.
     PubMed     Abstract available
     
     
     
146. STERLING RK, King WC, Khalili M, Chung RT, et al
     A Prospective Study Evaluating Changes in Histology, Clinical and Virologic Outcomes in HBV-HIV Co-infected Adults in North America.
     Hepatology. 2021;74:1174-1189.
     PubMed     Abstract available
     
     
     
147. TOMLINSON JE, Wolfisberg R, Fahnoe U, Patel RS, et al
     Pathogenesis, MicroRNA-122 Gene-Regulation, and Protective Immune Responses After Acute Equine Hepacivirus Infection.
     Hepatology. 2021;74:1148-1163.
     PubMed     Abstract available
     
     
     August 2021
148. WANG CW, Grab J, Tana MM, Irani RA, et al
     Outcomes of Pregnancy in Autoimmune Hepatitis: A Population-Based Study.
     Hepatology. 2021 Aug 28. doi: 10.1002/hep.32132.
     PubMed     Abstract available
     
     
     
149. WEI L, Zhao T, Zhang J, Mao Q, et al
     Efficacy and Safety of a Nanoparticle Therapeutic Vaccine in Patients with Chronic Hepatitis B: A Randomized Clinical Trial.
     Hepatology. 2021 Aug 15. doi: 10.1002/hep.32109.
     PubMed     Abstract available
     
     
     
150. LI Y, Yu P, Kessler AL, Shu J, et al
     Hepatitis E virus infection activates NLRP3 inflammasome antagonizing interferon response but therapeutically targetable.
     Hepatology. 2021 Aug 15. doi: 10.1002/hep.32114.
     PubMed     Abstract available
     
     
     
151. YIP TC, Wong VW, Wong GL
     Reply to Letters to the Editor: Clinical outcomes in COVID-19 patients with current or past hepatitis B virus infection.
     Hepatology. 2021 Aug 15. doi: 10.1002/hep.32116.
     PubMed     Abstract available
     
     
     
152. JINDAL A
     Outcomes in chronic hepatitis B infection and COVID-19 - Not always benign !
     Hepatology. 2021 Aug 13. doi: 10.1002/hep.32108.
     PubMed     Abstract available
     
     
     
153. OECHSLIN N, Da Silva N, Szkolnicka D, Cantrelle FX, et al
     Hepatitis E Virus RNA-Dependent RNA Polymerase is Involved in RNA Replication and Infectious Particle Production.
     Hepatology. 2021 Aug 13. doi: 10.1002/hep.32100.
     PubMed     Abstract available
     
     
     
154. LV XH, Yang JL, Deng K
     Letter to the Editor: unanswered questions about hepatitis B virus infection in patients with COVID-19.
     Hepatology. 2021 Aug 13. doi: 10.1002/hep.32098.
     PubMed     Abstract available
     
     
     
155. MUSTO J, Stanfield D, Ley D, Lucey MR, et al
     Recovery and Outcomes of Patients Denied Early Liver Transplantation (LT) for Severe Alcohol-Related Hepatitis (AH).
     Hepatology. 2021 Aug 13. doi: 10.1002/hep.32110.
     PubMed     Abstract available
     
     
     
156. HLADY RA, Zhao X, El Khoury LY, Luna A, et al
     Interferon drives hepatitis C virus scarring of the epigenome and creates targetable vulnerabilities following viral clearance.
     Hepatology. 2021 Aug 13. doi: 10.1002/hep.32111.
     PubMed     Abstract available
     
     
     
157. TOYODA H, Leong J, Landis C, Atsukawa M, et al
     Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice.
     Hepatology. 2021;74:656-666.
     PubMed     Abstract available
     
     
     
158. LIANG YJ, Teng W, Chen CL, Sun CP, et al
     Clinical Implications of HBV PreS/S Mutations and the Effects of PreS2 Deletion on Mitochondria, Liver Fibrosis, and Cancer Development.
     Hepatology. 2021;74:641-655.
     PubMed     Abstract available
     
     
     July 2021
159. LOK AS, Negro F, Asselah T, Farci P, et al
     Endpoints and new options for treatment of chronic hepatitis D.
     Hepatology. 2021 Jul 31. doi: 10.1002/hep.32082.
     PubMed     Abstract available
     
     
     
160. CHOLANKERIL G, Goli K, Rana A, Hernaez R, et al
     Impact of COVID-19 pandemic on liver transplantation and alcohol-associated liver disease in the United States.
     Hepatology. 2021 Jul 26. doi: 10.1002/hep.32067.
     PubMed     Abstract available
     
     
     
161. MCMAHON BJ, Nolen S, Snowball M, Homan C, et al
     Hepatitis B Virus (HBV) Genotype: A Significant Risk Factor in Determining which Patients with Chronic HBV Infection should Undergo Surveillance for Hepatocellular Carcinoma: The Hepatitis B Alaska (HEP-B-AK) Study.
     Hepatology. 2021 Jul 22. doi: 10.1002/hep.32065.
     PubMed     Abstract available
     
     
     
162. SULKOWSKI MS, Moon J, Sherman K, Morelli G, et al
     A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: THE PRIORITIZE STUDY.
     Hepatology. 2021 Jul 13. doi: 10.1002/hep.32053.
     PubMed     Abstract available
     
     
     
163. KIM OK, Nam DE, Hahn YS
     The Panx1/P2X4 pathway controls the secretion of miRNA-containing exosomes by HCV-infected hepatocytes.
     Hepatology. 2021 Jul 4. doi: 10.1002/hep.32042.
     PubMed     Abstract available
     
     
     
164. CHO Y, Szabo G
     Two Faces of Neutrophils in Liver Disease Development and Progression.
     Hepatology. 2021;74:503-512.
     PubMed     Abstract available
     
     
     June 2021
165. NGUYEN LN, Nguyen LNT, Zhao J, Schank M, et al
     Immune activation induces telomeric DNA damage and promotes short-lived effector T cell differentiation in chronic HCV infection.
     Hepatology. 2021 Jun 10. doi: 10.1002/hep.32008.
     PubMed     Abstract available
     
     
     
166. BEUDEKER BJB, Janssen HLA, Boonstra A
     Letter to the Editor: Entecavir treatment restores the anti-hepatitis B virus immune response?
     Hepatology. 2021 Jun 9. doi: 10.1002/hep.32003.
     PubMed     Abstract available
     
     
     
167. DE PASQUALE C, Campana S, Pollicino T, Ferlazzo G, et al
     Letter to the Editor: Entecavir treatment restores the anti-hepatitis B virus immune response? Author's Reply.
     Hepatology. 2021 Jun 9. doi: 10.1002/hep.32004.
     PubMed     Abstract available
     
     
     
168. LIM AG, Stone J, Hajarizadeh B, Byrne M, et al
     Evaluating the prevention benefit of HCV treatment: Modelling the SToP-C treatment as prevention study in prisons.
     Hepatology. 2021 Jun 9. doi: 10.1002/hep.32002.
     PubMed     Abstract available
     
     
     
169. ROBERTS H, Ly KN, Yin S, Hughes E, et al
     Prevalence of Hepatitis B Virus (HBV) Infection, Vaccine-Induced Immunity, and Susceptibility among At-Risk Populations: U.S. Households, 2013-2018.
     Hepatology. 2021 Jun 7. doi: 10.1002/hep.31991.
     PubMed     Abstract available
     
     
     
170. YANG Z, Zhang T, Kusumanchi P, Tang Q, et al
     Transcriptomic analysis reveals the miRNAs responsible for liver regeneration associated with mortality in alcoholic hepatitis.
     Hepatology. 2021 Jun 7. doi: 10.1002/hep.31994.
     PubMed     Abstract available
     
     
     
171. CHOI J, Yoo S, Lim YS
     Comparison of Long-Term Clinical Outcomes Between Spontaneous and Therapy-Induced HBsAg Seroclearance.
     Hepatology. 2021;73:2155-2166.
     PubMed     Abstract available
     
     
     May 2021
172. GANE E, Yuen MF, Kim DJ, Chan HL, et al
     Clinical Study of Single Stranded Oligonucleotide RO7062931 in Healthy Volunteers and Patients with Chronic Hepatitis B.
     Hepatology. 2021 May 26. doi: 10.1002/hep.31920.
     PubMed     Abstract available
     
     
     
173. MESZAROS M, Truchi R, Ouzan D, Tran A, et al
     Sofosbuvir, glecaprevir, pibrentasvir, and ribavirin as a rescue therapy in difficult-to-treat hepatitis C patients.
     Hepatology. 2021 May 18. doi: 10.1002/hep.31909.
     PubMed     Abstract available
     
     
     
174. CLIPMAN SJ, Mehta SH, Rodgers MA, Duggal P, et al
     Spatiotemporal phylodynamics of hepatitis C among people who inject drugs in India.
     Hepatology. 2021 May 18. doi: 10.1002/hep.31912.
     PubMed     Abstract available
     
     
     
175. RIEDL T, Faure-Dupuy S, Rolland M, Schuehle S, et al
     HIF1alpha-mediated RelB/APOBEC3B downregulation allows Hepatitis B Virus persistence.
     Hepatology. 2021 May 15. doi: 10.1002/hep.31902.
     PubMed     Abstract available
     
     
     
176. YIP TC, Wong VW, Lui GC, Chow VC, et al
     Current and past infections of hepatitis B virus do not increase mortality in patients with COVID-19.
     Hepatology. 2021 May 7. doi: 10.1002/hep.31890.
     PubMed     Abstract available
     
     
     
177. LIAO H, Wang J, Liu Y, Chen J, et al
     Letter to the Editor: Why Serum Hepatitis B Virus (HBV) DNA Has Higher Frequency of rtM204I/V Mutation Than Serum HBV RNA in the Same Individual?
     Hepatology. 2021;73:2075-2076.
     PubMed    
     
     
     
178. BRUNT EM, Kleiner DE, Carpenter DH, Rinella M, et al
     NAFLD: Reporting Histologic Findings in Clinical Practice.
     Hepatology. 2021;73:2028-2038.
     PubMed     Abstract available
     
     
     April 2021
179. ISHIKAWA T, Sasaki R, Matsuda T, Saeki I, et al
     Successful Management with Dual Therapy of Lenvatinib and Macitentan for Hepatocellular Carcinoma with Portopulmonary Hypertension.
     Hepatology. 2021 Apr 26. doi: 10.1002/hep.31865.
     PubMed     Abstract available
     
     
     
180. LIU Y, Wang S, Hu L
     Letter to the Editor: Use of New Defined Metabolic Risk Factors in Patients with Chronic Hepatitis B.
     Hepatology. 2021 Apr 8. doi: 10.1002/hep.31842.
     PubMed     Abstract available
     
     
     
181. LEE YB, Lee J
     Letter to the Editor: Use of New Defined Metabolic Risk Factors in Patients with Chronic Hepatitis B - The Authors' reply.
     Hepatology. 2021 Apr 2. doi: 10.1002/hep.31844.
     PubMed     Abstract available
     
     
     
182. JONAS MM, Rhee S, Kelly DA, Del Valle-Segarra A, et al
     Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in children with chronic hepatitis C virus: part 2 of the DORA study.
     Hepatology. 2021 Apr 2. doi: 10.1002/hep.31841.
     PubMed     Abstract available
     
     
     
183. ABUTALEB A, Khatun M, Clement J, Baidya A, et al
     A Model of Care Optimized for Marginalized Remote Population Unravels Migration Pattern in India.
     Hepatology. 2021;73:1261-1274.
     PubMed     Abstract available
     
     
     February 2021
184. YAMASHITA T, Koshikawa N, Shimakami T, Terashima T, et al
     Serum laminin gamma2 monomer as a novel diagnostic and predictive biomarker for hepatocellular carcinoma.
     Hepatology. 2021 Feb 20. doi: 10.1002/hep.31758.
     PubMed     Abstract available
     
     
     
185. CHEMIN I, Pujol FH, Scholtes C, Loureiro CL, et al
     Preliminary Evidence for Hepatitis Delta Virus Exposure in Patients Who Are Apparently Not Infected With Hepatitis B Virus.
     Hepatology. 2021;73:861-864.
     PubMed    
     
     
     
186. KIM GW, Imam H, Khan M, Mir SA, et al
     HBV-Induced Increased N6 Methyladenosine Modification of PTEN RNA Affects Innate Immunity and Contributes to HCC.
     Hepatology. 2021;73:533-547.
     PubMed     Abstract available
     
     
     
187. CHEN J, Li Y, Lai F, Wang Y, et al
     Functional Comparison of Interferon-alpha Subtypes Reveals Potent Hepatitis B Virus Suppression by a Concerted Action of Interferon-alpha and Interferon-gamma Signaling.
     Hepatology. 2021;73:486-502.
     PubMed     Abstract available
     
     
     
188. ZHAO X, Fan H, Chen X, Zhao X, et al
     Hepatitis B Virus DNA Polymerase Restrains Viral Replication Through the CREB1/HOXA Distal Transcript Antisense RNA Homeobox A13 Axis.
     Hepatology. 2021;73:503-519.
     PubMed     Abstract available
     
     
     November 2020
189. HAFEZI M, Lin M, Chia A, Chua A, et al
     Immunosuppressive Drug Resistant Armored TCR T cells for immune-therapy of HCC in liver transplant patients.
     Hepatology. 2020 Nov 29. doi: 10.1002/hep.31662.
     PubMed     Abstract available
     
     
     
190. BERTOLETTI A
     ImmTAV, a New Immunotherapy Targeting the Source of HBV Infection.
     Hepatology. 2020;72:1514-1517.
     PubMed    
     
     
     September 2020
191. ZHAO Q, Guo JT
     Have the Starting Lineup of Five for Hepatitis B Virus Covalently Closed Circular DNA Synthesis Been Identified?
     Hepatology. 2020;72:1142-1144.
     PubMed    
     
     
     August 2020
192. KAPILA N, Rahman AU, Zervos XB
     Reply.
     Hepatology. 2020;72:788.
     PubMed    
     
     
     July 2020
193. THAN NN, Cataluna JG, Majumdar A
     Acute confusion post liver transplantation: HE or not HE, that is the question.
     Hepatology. 2020 Jul 6. doi: 10.1002/hep.31452.
     PubMed     Abstract available
     
     
     
194. CRESCI GAM
     Is It Time to Consider Gut Microbiome Readouts for Precision Diagnosis and Treatment of Alcoholic Liver Disease?
     Hepatology. 2020;72:4-6.
     PubMed    
     
     
     April 2020
195. BEYLS C, Haustermans K, Deroose CM, Pans S, et al
     Could autoimmune disease contribute to the abscopal effect in metastatic hepatocellular carcinoma?
     Hepatology. 2020 Apr 29. doi: 10.1002/hep.31186.
     PubMed     Abstract available
     
     
     
196. MCGLYNN KA, Petrick JL, El-Serag HB
     Epidemiology of Hepatocellular Carcinoma.
     Hepatology. 2020 Apr 22. doi: 10.1002/hep.31288.
     PubMed     Abstract available
     
     
     
197. YANG Y, Zhao X, Wang Z, Shu W, et al
     Nuclear Sensor Interferon-Inducible Protein 16 Inhibits the Function of Hepatitis B Virus Covalently Closed Circular DNA by Integrating Innate Immune Activation and Epigenetic Suppression.
     Hepatology. 2020;71:1154-1169.
     PubMed     Abstract available
     
     
     March 2020
198. SZE KM, Ho DW, Chiu YT, Tsui YM, et al
     HBV-TERT Promoter Integration Harnesses Host ELF4 Resulting in TERT Gene Transcription in Hepatocellular Carcinoma.
     Hepatology. 2020 Mar 14. doi: 10.1002/hep.31231.
     PubMed     Abstract available
     
     
     
199. ZENG J, Wu D, Hu H, Young JAT, et al
     Activation of the liver X receptor pathway inhibits HBV replication in primary human hepatocytes.
     Hepatology. 2020 Mar 7. doi: 10.1002/hep.31217.
     PubMed     Abstract available
     
     
     December 2019
200. STUART L, Lambourne B, Turner P, Jones DE, et al
     HEP-19-1549 Pembrolizumab as a cause of cholangiopathy in a patient with metastatic melanoma.
     Hepatology. 2019 Dec 23. doi: 10.1002/hep.31089.
     PubMed     Abstract available
     
     
     October 2019
201. LIU F, Goh GB, Tiniakos D, Wee A, et al
     qFIBS: A Novel Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis.
     Hepatology. 2019 Oct 10. doi: 10.1002/hep.30986.
     PubMed     Abstract available
     
     
     September 2019
202. LEVITSKY J, Asrani SK, Klintmalm G, Schiano T, et al
     Discovery and validation of a biomarker model (preserve) predictive of renal outcomes after liver transplantation.
     Hepatology. 2019 Sep 11. doi: 10.1002/hep.30939.
     PubMed     Abstract available
     
     
     
203. DONG B, Zhou Y, Wang W, Scott J, et al
     Vitamin D receptor activation in liver macrophages ameliorates hepatic inflammation, steatosis, and insulin resistance in mice.
     Hepatology. 2019 Sep 11. doi: 10.1002/hep.30937.
     PubMed     Abstract available
     
     
     August 2019
204. MATYAS C, Erdelyi K, Trojnar E, Zhao S, et al
     Interplay of liver-heart inflammatory axis and cannabinoid 2 receptor signalling in an experimental model of hepatic cardiomyopathy.
     Hepatology. 2019 Aug 30. doi: 10.1002/hep.30916.
     PubMed     Abstract available
     
     
     
205. ZHOU Y, Dong B, Kim KH, Choi S, et al
     Vitamin D receptor activation in liver macrophages protects against hepatic endoplasmic reticulum stress in mice.
     Hepatology. 2019 Aug 5. doi: 10.1002/hep.30887.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: